blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2467163

EP2467163 - MIMOTOPES OF HIV AND USES THEREOF [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  07.08.2015
Database last updated on 05.07.2024
Most recent event   Tooltip07.08.2015Application deemed to be withdrawnpublished on 09.09.2015  [2015/37]
Applicant(s)For all designated states
Dana-Farber Cancer Institute, Inc.
450 Brookline Avenue
Boston, MA 02215 / US
[2012/26]
Inventor(s)01 / HUMBERT, Michael
200 Northampton Street 4
Boston, MA 02118 / US
02 / RUPRECHT, Ruth, M.
127 Winthrop Road, Apt. 6
Brookline, MA 02445 / US
03 / SHOLUKH, Anton, M.
90 Brainard Road 10
Allston, MA 02134 / US
 [2012/26]
Representative(s)Hiebl, Inge Elisabeth
Kraus & Weisert
Patentanwälte PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
[N/P]
Former [2012/26]Hiebl, Inge Elisabeth
Kraus & Weisert Patent- und Rechtsanwälte Thomas-Wimmer-Ring 15
80539 München / DE
Application number, filing date10810720.223.08.2010
WO2010US46353
Priority number, dateUS20090235942P21.08.2009         Original published format: US 235942 P
US20100351637P04.06.2010         Original published format: US 351637 P
[2012/26]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2011022725
Date:24.02.2011
Language:EN
[2011/08]
Type: A2 Application without search report 
No.:EP2467163
Date:27.06.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 24.02.2011 takes the place of the publication of the European patent application.
[2012/26]
Search report(s)International search report - published on:KR04.08.2011
ClassificationIPC:A61K39/395, A61K38/16, C12N15/86, C12N5/10, C12N5/0781, C07K16/10, A61P31/18
[2012/26]
CPC:
C07K16/1063 (EP,US); A61P31/04 (EP); A61P31/10 (EP);
A61P31/12 (EP); A61P31/18 (EP); A61P33/00 (EP);
A61P33/02 (EP); A61P37/04 (EP); C07K14/005 (EP,US);
A61K38/00 (EP,US); C07K2317/21 (EP,US); C07K2317/76 (EP,US);
C07K2319/735 (EP,US); C12N2740/15022 (EP,US); C12N2740/16122 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/26]
TitleGerman:MIMOTOPE VON HIV UND ANWENDUNGEN DAVON[2012/26]
English:MIMOTOPES OF HIV AND USES THEREOF[2012/26]
French:MIMOTOPES DU VIH ET LEURS UTILISATIONS[2012/26]
Entry into regional phase19.03.2012National basic fee paid 
19.03.2012Search fee paid 
19.03.2012Designation fee(s) paid 
19.03.2012Examination fee paid 
Examination procedure19.03.2012Examination requested  [2012/26]
05.11.2012Amendment by applicant (claims and/or description)
03.03.2015Application deemed to be withdrawn, date of legal effect  [2015/37]
15.04.2015Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2015/37]
Fees paidRenewal fee
27.08.2012Renewal fee patent year 03
27.08.2013Renewal fee patent year 04
Penalty fee
Additional fee for renewal fee
31.08.201405   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[A]US6455265  (SERRES PIERRE-FRANCOIS [FR])
 [X]  - GOUDSMIT, J. ET AL., "Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.", PROC. NATL. ACAD. SCI. U. S. A., (198806), vol. 85, no. 12, pages 4478 - 4482, XP008153857

DOI:   http://dx.doi.org/10.1073/pnas.85.12.4478
 [A]  - HE, Y. ET AL., "Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci.", J. IMMUNOL., (20020701), vol. 169, no. 1, pages 595 - 605, XP008153860

DOI:   http://dx.doi.org/10.4049/jimmunol.169.1.595
 [A]  - PAUL, S. ET AL., "Naturally occurring proteolytic antibodies: selective immunoglobulin M-catalyzed hydrolysis of HIV gp120.", J. BIOL. CHEM., (20040721), vol. 279, no. 38, pages 39611 - 39619, XP008153850

DOI:   http://dx.doi.org/10.1074/jbc.M406719200
 [A]  - JOYCE, J. G. ET AL., "An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions.", PROC. NATL. ACAD. SCI. U. S. A., (20081006), vol. 105, no. 41, pages 15684 - 15689, XP008153861

DOI:   http://dx.doi.org/10.1073/pnas.0807837105
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.